Please use this identifier to cite or link to this item:
Title: A systematic review of drug-carrying nanosystems used in the treatment of leishmaniasis.
Authors: Registre, Charmante
Soares, Rodrigo Dian de Oliveira Aguiar
Rúbio, Karina Taciana Santos
Santos, Orlando David Henrique dos
Carneiro, Simone Pinto
Keywords: Nanotechnology
Drug delivery
Antileishmanial drugs
Issue Date: 2023
Citation: REGISTRE, C. et al. A systematic review of drug-carrying nanosystems used in the treatment of leishmaniasis. ACS Infectious Diseases, v. 9, p. 423−449, 2023. Disponível em: <>. Acesso em: 01 ago. 2023.
Abstract: Leishmaniasis is an infectious disease responsible for a huge rate of morbidity and mortality in humans. Chemotherapy consists of the use of pentavalent antimonial, amphotericin B, pentamidine, miltefosine, and paromomycin. However, these drugs are associated with some drawbacks such as high toxicity, administration by parenteral route, and most seriously the resistance of some strains of the parasite to them. Several strategies have been used to increase the therapeutic index and reduce the toxic effects of these drugs. Among them, the use of nanosystems that have great potential as a site-specific drug delivery system stands out. This review aims to compile results from studies that were carried out using first- and second-line antileishmanial drug- carrying nanosystems. The articles referred to here were published between 2011 and 2021. This study shows the promise of effective applicability of drug-carrying nanosystems in the field of antileishmanial therapeutics, with the perspective of providing better patient adherence to treatment, increased therapeutic efficacy, reduced toxicity of conventional drugs, as well as the potential to efficiently improve the treatment of leishmaniasis.
ISSN: 2373-8227
Appears in Collections:DEFAR - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
  Restricted Access
6,38 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.